Vascular Biogenics reported 30K in Gross Profit on Sales for its second fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Gross Profit On Sales Change
Bluebird Bio BLUE:US $ -226000 6.14M
Epizyme EPZM:US $ 22.36M 16.3M
Infinity Pharmaceuticals INFI:US $ 0.27M 0.01M
Vascular Biogenics VBLT:US 30K 28K